Oral Hypoglycemic Sulfonylurea
Shortepa - 1
Glimepiride Tablets IP 1mg
Second-generation sulfonylurea formulation that stimulates pancreatic beta-cell insulin secretion with lower risk of severe hypoglycemia for Type 2 diabetes management.
Standardized Actives
Glimepiride IP 1mg (Second-generation sulfonylurea).
Therapeutic Purpose
- Type 2 Diabetes Mellitus glycemic control as monotherapy
- Dual combination therapy alongside Metformin or Thiazolidinediones
- Fasting and postprandial blood glucose stabilization
Administration & Care
Initial dose 1mg once daily with breakfast; titrated as directed by Diabetologist.
Strip of 10 / 15 tablets in Alu-Alu moisture-barrier blister. — Store below 25°C. Protect from moisture and excessive heat.
Quality, Safety & Manufacturing Standards
Every batch of Aanav Healthcare formulations is manufactured under strict current Good Manufacturing Practices (cGMP) in licensed facilities in Mumbai, India. We subject all active pharmaceutical ingredients and botanical extracts to multi-stage purity, stability, and assay tests.
- Product Title
- Shortepa - 1 (Glimepiride Tablets IP 1mg)
- Therapeutic Segment
- Oral Hypoglycemic Sulfonylurea — Diabetology
- Active Formula
- Glimepiride IP 1mg (Second-generation sulfonylurea).
- Dosage & Use
- Initial dose 1mg once daily with breakfast; titrated as directed by Diabetologist.
- Pack Packaging
- Strip of 10 / 15 tablets in Alu-Alu moisture-barrier blister.
- Storage Guidelines
- Store below 25°C. Protect from moisture and excessive heat.
- Regulatory Compliance
- Schedule H Prescription Drug — cGMP Certified.
Other Formulations in Diabetology
Oral Hypoglycemic Sulfonylurea
Shortepa - 2
Advanced 2mg Glimepiride formulation providing 24-hour glycemic control for diabetic patients requiring enhanced pancreatic insulin secretory support.
DPP-4 Inhibitor & Biguanide Combination
Tinashe
Fixed-dose combination of a potent, selective DPP-4 inhibitor and sustained-release metformin for comprehensive 24-hour glycemic control without weight gain.
Dual Oral Anti-Diabetic Formulation
Drglim - M2
Synergistic combination targeting both pancreatic insulin secretion and peripheral insulin resistance for long-term target HbA1c maintenance.